Results 11 to 20 of about 765,049 (358)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. [PDF]
New England Journal of Medicine, 2019 BACKGROUND Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
O. Distler +14 more
semanticscholar +5 more sources
Respiratory Research, 2023 Introduction Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associated with worse clinical outcome ...
Iris G. van der Sar +6 more
doaj +1 more source
European Respiratory Review, 2021 Rheumatoid arthritis (RA) is a systemic inflammatory disorder, with the most common extra-articular manifestation of RA being lung involvement. While essentially any of the lung compartments can be affected and manifest as interstitial lung disease (ILD),
S. Kadura, G. Raghu
semanticscholar +1 more source
Arthritis & Rheumatology, 2022 To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.
E. Matteson +14 more
semanticscholar +1 more source
Predictors and changes of physical activity in idiopathic pulmonary fibrosis
BMC Pulmonary Medicine, 2022 Background Different clinical predictors of physical activity (PA) have been described in idiopathic pulmonary fibrosis (IPF), but studies are lacking evaluating the potential role of muscle strength and anxiety and depression symptoms in PA limitation ...
Diana Badenes-Bonet +15 more
doaj +1 more source
Immunomodulatory treatment of interstitial lung disease
Therapeutic Advances in Respiratory Disease, 2022 Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array of immunomodulatory treatment options compared with IPF, due to their inflammatory component.
L. van den Bosch +3 more
semanticscholar +1 more source
Variability in Global Prevalence of Interstitial Lung Disease
Frontiers in Medicine, 2021 There are limited epidemiologic studies describing the global burden and geographic heterogeneity of interstitial lung disease (ILD) subtypes. We found that among seventeen methodologically heterogenous studies that examined the incidence, prevalence and
B. Kaul +3 more
semanticscholar +1 more source
BMJ Open Respiratory Research, 2021 Introduction Antisynthetase syndrome (ASyS) is a rare autoimmune connective tissue disease (CTD), associated with autoantibodies targeting tRNA synthetase enzymes, that can present to respiratory (interstitial lung disease (ILD)) or rheumatology ...
Harsha Gunawardena +7 more
doaj +1 more source
In-hospital mortality following surgical lung biopsy for interstitial lung disease in the USA: 2000-2011 [PDF]
, 2016 Rationale: Surgical lung biopsy can help to determine a specific diagnosis in interstitial lung disease, but has associated risks. Most currently available mortality data are derived from case series and may not be generalizable to broader populations.
Fogarty, Andrew W. +3 more
core +1 more source
Lung function trajectory in progressive fibrosing interstitial lung disease
European Respiratory Journal, 2021 Background Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD) have been linked to increased mortality risk, but lung function trajectory after satisfying individual criteria remains unknown. Because survival is rarely employed
J. Oldham +15 more
semanticscholar +1 more source